Genetic Signatures (GSS) Q4 2025 TU earnings summary

Executive summary

• Quarterly sales reached $4.4 million, matching the prior year period and up 52% sequentially, driven by higher Australian winter respiratory testing rates.

• Organisational restructuring included US leadership changes and targeted redundancies to align resources with strategic priorities.

• US sales ramp-up delayed by customer internal processes and market uncertainty; a new US contract was signed post-quarter.

• Strategic three-way partnership launched to develop automated, high-throughput solutions, enhancing workflow and global competitiveness.

• Strong global engagement with molecular experts, with key opinion leaders presenting at major conferences.

Financial highlights

• Receipts from customers were $3.6 million, up 67.5% year-over-year, mainly from Australian sales.

• Net operating cash outflow was $5.95 million, reflecting increased inventory investment for the winter season.

• Cash and cash equivalents at quarter-end totaled $30.9 million.

• Net investing cash outflows were $0.2 million, primarily for equipment and R&D lab investments.

• No new financing activities; principal lease payments were $0.1 million for the quarter.

Outlook and guidance

• Focus remains on maintaining and growing the Australian footprint while expanding in the US and UK.

• Strong cash position supports ongoing commercial initiatives and innovation in assay development and workflow optimisation.